Joby Aviation prepares first conforming aircraft for final assembly
Investing.com - BioCryst (NASDAQ: BCRX) reported second quarter EPS of $0.150, $0.14 better than the analyst estimate of $0.010. Revenue for the quarter came in at $163.35M versus the consensus estimate of $149.82M.
Guidance
BioCryst sees FY 2025 revenue of $580.000M-$600.000M versus the analyst consensus of $608.400M.
BioCryst’s stock price closed at $7.95. It is down -21.130% in the last 3 months and up 5.860% in the last 12 months.
BioCryst saw 4 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See BioCryst’s stock price’s past reactions to earnings here.
According to InvestingPro, BioCryst’s Financial Health score is "good performance".
Check out BioCryst’s recent earnings performance, and BioCryst’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar